Please login to the form below

Not currently logged in
Email:
Password:

multiple sclerosis

This page shows the latest multiple sclerosis news and features for those working in and with pharma, biotech and healthcare.

FDA approves expanded use of BMS’ Reblozyl in blood disorders

FDA approves expanded use of BMS’ Reblozyl in blood disorders

by BMS, along with just-approved multiple sclerosis drug Zeposia, CAR-Ts liso-cel and ide-cel and Inrebic (fedratinib) for myelofibrosis.

Latest news

More from news
Approximately 84 fully matching, plus 502 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Elsewhere, BMS will need new Celgene prospects like selective JAK2 inhibitor Inrebic (fedratinib) – the first new myelofibrosis therapy in a decade – as well as other new drug candidates like multiple sclerosis ... The following month J&J agreed to a

  • Case study: OptiMiSe for MS nurses Case study: OptiMiSe for MS nurses

    OptiMiSe was launched in 2016 to support Multiple Sclerosis Specialist Nurses (MSSNs) in the provision of individualised care to patients living with MS.

  • Case study: What we're made of Case study: What we're made of

    This could be a side effect of a condition such as stroke, motor neurone disease, multiple sclerosis, learning disability, dementia, Parkinson’s disease, head and neck injury or cancer.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    4. Mayzent – a latest addition to competitive MS market. Novartis’ Mayzent (siponimod) is expected to be launched in the US in Q1 for multiple sclerosis, with an EU launch to follow ... EvaluatePharma has predicted it could become a nearly $2.5bn

  • Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available? Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?

    In the past, specialised infusion centres have been established to provide outpatient infusion therapy administered by nurses to multiple sclerosis patients in Germany.

More from intelligence
Approximately 0 fully matching, plus 34 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 25 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 16 fully matching, plus 26 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics